Delayed nausea and vomiting from carboplatin doublet chemotherapy

References

• Schnell FM. Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control. Oncologist 2003;8:187–98.
   PubMed Web of Science ®Google Scholar
• Lohr L. Chemotherapy-induced nausea and vomiting. Cancer J 2008;14:85–93.
   PubMed Web of Science ®Google Scholar
• Navari RM. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting-two new agents. J Support Oncol 2003;1:89–103.
   PubMedGoogle Scholar
• Kris MG, Gralla RJ, Clark RA, Tyson LB, O'connell JP, Wertheim MS, et al. Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 1985;3:1379–84.
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Grunberg SM, Herrstedt J, de Wit R, Gralla RJ, Carides AD, et al. Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. Support Care Cancer 2006;14:354–60.
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol1997;15:103–9.
   PubMed Web of Science ®Google Scholar
• Du Bois A, Vach W, Kiechle M, Cramer-Giraud U, Meerpohl HG. Pathophysiology, severity, pattern, and risk factors for carboplatin-induced emesis. Oncology 1996;53(Suppl 1):46–50.
   PubMed Web of Science ®Google Scholar
• Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 2010;21:v232–43.
   PubMed Web of Science ®Google Scholar
• Martin AR, Pearson JD, Cai B, Elmer M, Horgan K, Lindley C. Assessing the impact of chemotherapy-induced nausea and vomiting on patients' daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall. Support Care Cancer 2003;11:522–7.
   PubMed Web of Science ®Google Scholar
• Martin AR, Carides AD, Pearson JD, Horgan K, Elmer M, Schmidt C, et al. Functional relevance of antiemetic control. Experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant. Eur J Cancer 2003;39:1395–401.
   PubMed Web of Science ®Google Scholar
• Schipper H, Clinch J, McMurray A, Levitt M. Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation. J Clin Oncol 1984;2:472–83.
   PubMed Web of Science ®Google Scholar
• Vandereycken W, Pierloot R. Drop-out during in-patient treatment of anorexia nervosa: a clinical study of 133 patients.Br J Med Psych 1983;56 (Pt 2):145–56.
   PubMed Web of Science ®Google Scholar
• Morlino M, Di Pietro G, Tuccillo R, Galietta A, Bolzan M, Senatore I, et al. Drop-out rate in eating disorders: could it be a function of patient-therapist relationship? Eat Weight Disord EWD 2007;12:e64–7.
   Google Scholar
• Waqar MA, Chitneni P, Williams K, Goodgame BW, Gao F, Govindan R, et al. A prospective study on the incidence of delayed nausea and vomiting following administration of carboplatin containing regimens for treatment of cancer without prophylactic aprepitant. ASCO Meeting Abstracts 2008;26:20626
   Google Scholar
• Ito Y, Karayama M, Inui N, Kuroishi S, Nakano H, Nakamura Y, et al. Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy. Lung Cancer 2014;84:259–64.
   PubMed Web of Science ®Google Scholar
• Jordan K, Jahn F, Aapro M. Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review. Ann Oncol 2015;26:1081–90.
   PubMed Web of Science ®Google Scholar
• Tanioka M, Kitao A, Matsumoto K, Shibata N, Yamaguchi S, Fujiwara K, et al. A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy. Br J Cancer 2013;109:859–65.
   PubMed Web of Science ®Google Scholar
• Yahata H, Kobayashi H, Sonoda K, Shimokawa M, Ohgami T, Saito T, et al. Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin. Int J Clin Oncol 2015. [Epub ahead of print]. DOI: 10.1007/s10147-015-0928-y.
   PubMed Web of Science ®Google Scholar
• van der Vorst MJ, Neefjes EC, Konings IR, Verheul HM. Prophylactic treatment for delayed chemotherapy-induced nausea and vomiting after non-AC based moderately emetogenic chemotherapy: a systematic review of randomized controlled trials. Support Care Cancer 2015;23:2499–506.
   PubMed Web of Science ®Google Scholar